162 related articles for article (PubMed ID: 28952656)
1. Primary Cutaneous CD30+ Lymphoproliferative Disorders in a Patient with Severe Atopic Dermatitis: Is There a Causative Link?
Zychowska M; Woźniak Z; Maj J
Acta Derm Venereol; 2018 Jan; 98(1):123-125. PubMed ID: 28952656
[No Abstract] [Full Text] [Related]
2. Lymphomatoid Papulosis and Other Lymphoma-Like Diseases.
Moy A; Sun J; Ma S; Seminario-Vidal L
Dermatol Clin; 2019 Oct; 37(4):471-482. PubMed ID: 31466587
[TBL] [Abstract][Full Text] [Related]
3. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
4. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
5. Perils and pitfalls regarding differential diagnosis and treatment of primary cutaneous anaplastic large-cell lymphoma.
Diamantidis MD; Myrou AD
ScientificWorldJournal; 2011 May; 11():1048-55. PubMed ID: 21552770
[TBL] [Abstract][Full Text] [Related]
6. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Pfaltz K; Vermeer MH; Cozzio A; Ortiz-Romero PL; Bagot M; Olsen E; Kim YH; Dummer R; Pimpinelli N; Whittaker S; Hodak E; Cerroni L; Berti E; Horwitz S; Prince HM; Guitart J; Estrach T; Sanches JA; Duvic M; Ranki A; Dreno B; Ostheeren-Michaelis S; Knobler R; Wood G; Willemze R
Blood; 2011 Oct; 118(15):4024-35. PubMed ID: 21841159
[TBL] [Abstract][Full Text] [Related]
7. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
8. [Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis].
Slotosch CM; Hörster S; Hertl M; Schultz E
Hautarzt; 2010 Jun; 61(6):511-3. PubMed ID: 19536511
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous CD30+ lymphoproliferative disorder in an atopic dermatitis patient on cyclosporine therapy.
Nakamura S; Takeda K; Hashimoto Y; Mizumoto T; Ishida-Yamamoto A; Iizuka H
Indian J Dermatol Venereol Leprol; 2011; 77(2):253. PubMed ID: 21393977
[No Abstract] [Full Text] [Related]
10. CD30+ lymphoproliferative disorder with spindle-cell morphology.
Martires KJ; Cohen BE; Cassarino DS
J Cutan Pathol; 2016 Nov; 43(11):1041-1044. PubMed ID: 27433975
[TBL] [Abstract][Full Text] [Related]
11. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic Spread Is a Common Finding in Cutaneous CD30+ Lymphoproliferative Disorders.
Ferrara G; Ena L; Cota C; Cerroni L
Am J Surg Pathol; 2015 Nov; 39(11):1511-7. PubMed ID: 26371781
[TBL] [Abstract][Full Text] [Related]
13. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule.
Meisenheimer JL
J Drugs Dermatol; 2007 Apr; 6(4):440-2. PubMed ID: 17668543
[TBL] [Abstract][Full Text] [Related]
14. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
[TBL] [Abstract][Full Text] [Related]
15. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous CD30-positive lymphoproliferative disorders.
Willemze R; Meijer CJ
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1319-32, vii-viii. PubMed ID: 14710887
[TBL] [Abstract][Full Text] [Related]
18. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W; Kerl K; Mitteldorf C
Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
[TBL] [Abstract][Full Text] [Related]
20. Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training.
Sica A; Vitiello P; Ronchi A; Casale B; Calogero A; Sagnelli E; Costa Nachtigal G; Troiani T; Franco R; Argenziano G; Moscarella E; Sagnelli C
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32013101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
